Pfizer, BioNTech to flexibly 120 million doses of coronavirus immunization to Japan Kumar Jeetendra | July 31, 2020 Pfizer Inc and BioNTech SE have consented to provide Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday. The companies said, assuming achievement of the vaccine in clinical studies, they are on track to look for regulatory review to …
US to pay $2.1 billion to Sanofi, GSK in COVID-19 antibody bargain Kumar Jeetendra | July 31, 2020 The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc to get COVID-19 vaccines to pay 50 million individuals and to underwrite the drug manufacturers’ testing and manufacturing, the companies said on Friday. The award is the biggest yet from’Operation Warp Speed’, the White House initiative aimed at accelerating access to treatments …
U in Discussions to Procure Sanofi Bargain for coronavirus vaccine Kumar Jeetendra | August 1, 2020 Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine to the 27-country European Union. Equipped with an emergency fund of more than 2 billion euros (Â#1.80 billion), the European Commission would like to strike deals up to six drugmakers …
Try not to perspire it: Chilean canines track down coronavirus in beginning phases Kumar Jeetendra | August 1, 2020 Chilean police are training sniffer dogs to discover the coronavirus in people’s sweat for an early period, after a similar trial in the UK showed encouraging results. Four dogs are chosen for the initial training, a mixture of labradors and golden retrievers who game green”biodetector” jackets for their task. They are being trained at the …
Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
Russia to start mass inoculation crusade in October Kumar Jeetendra | August 2, 2020 In good news amid the surging novel coronavirus disease, Russia is preparing for a mass vaccination campaign against the novel coronavirus infection in October. Russia is the first state to finish the human clinical trial of a COVID-19 vaccine. Based on Russia’s Health Minister Mikhail Murashko, the Gamaleya Institute, a state research facility in Moscow, …
How antibody nationalism is hampering endeavors to end COVID-19 pandemic Kumar Jeetendra | August 2, 2020 The term of vaccine nationalism has entered our lexicon during H1N1 pandemic 2009, but has been used. But vaccine nationalism, has emerged as a real danger because of our ability to collectively finish the COVID-19 pandemic. So what’s vaccine nationalism? Vaccine nationalism involves countries procuring doses of vaccine for its own citizens or residents through …
FDA authorizes initial two COVID-19 serology tests Kumar Jeetendra | August 2, 2020 Today, the U.S. Food and Drug Administration approved the initial two COVID-19 serology tests which show an estimated amount of antibodies within somebody’s blood. Both tests from Siemens, the ADVIA Centaur COV2G and Attelica COV2G are what are known as”semi-quantitative” evaluations, meaning that they don’t show an exact measurement, but estimate the number of a …
Sterile 96-Well Plate Seal for Cell Culturing by BioChromato Kumar Jeetendra | August 2, 2020 BioChromato, Fujisawa, Japan, has introduced a gamma sterilized version of its Rapid Slit Seal for scientists seeking to eliminate solvent evaporation from samples when culturing cells from 96-well microplates. Rapid Slit Seal is a proprietary self-closing microplate seal which returns to its initial state even when punched having an HPLC or even LC/MS autosampler. This …
Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for healthcare professionals in acute care settings compared to traditional nebulisers Kumar Jeetendra | August 3, 2020 India has 18% of the global population and an increasing burden of chronic respiratory diseases1. The technique of nebulisation is commonly utilised in the treatment of such diseases including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD)2. Recent improvements in nebuliser technologies have led to the development of vibrating mesh nebulisers (VMNs) that produce …
Serum Institute gets DCGI gesture for stage 2 and 3 human clinical preliminaries of Oxford’s coronavirus immunization Kumar Jeetendra | August 3, 2020 The Drugs Controller General of India (DCGI) has contributed nod to the Serum Institute of India (SII) for conducting phase 3 and 2 human clinical trials of a COVID-19 vaccine candidate, developed at the University of Oxford, in the country. Government officials told PTI that the approval of conducting stage 2 and 3 clinical trials …
Protein delivered by the human safe framework can emphatically hinder Sars-Cov-2 Kumar Jeetendra | August 3, 2020 A protein produced by the human immune system may strongly inhibit corona viruses, including Sars-Cov-2, the pathogen causing Covid-19. An international team from Germany, Switzerland and the USA successfully showed the LY6E-Protein prevents coronaviruses from causing the illness. “This finding may result in the development of new therapeutic approaches against coronaviruses,” says Professor Stephanie Pfänder …
